Claris Bio Emerges From Stealth With a New Investor and Prepares for Next Development Stage With Late-Stage Data Expected in 1H24
04 janv. 2024 08h00 HE
|
Claris Biotherapeutics, Inc.
Claris Bio emerges from stealth with $57 million in funding as it prepares for 1H2024 readout of late-stage study in neurotrophic keratopathy
Cognition Therapeutics Announces Participation in Upcoming September Conferences
30 août 2023 08h00 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by...
Frontera Therapeutics Doses First Patient in a Clinical Trial of FT-003 Gene Therapy for the Treatment of Wet AMD
02 févr. 2023 09h00 HE
|
Frontera Therapeutics
BEDFORD, Mass. and SHANGHAI, China, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy...
Investigational Optejet® Microdose Dispenser from Eyenovia Shows Promise in Improving Treatment for Myopia, Presbyopia and Patients Getting Eye Exams
17 oct. 2022 09h01 HE
|
Eyenovia
NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Two recent studies show that the novel Optejet® dispenser from Eyenovia, Inc., an ophthalmic pharmaceutical technology company, may be a more...
Eyenovia Chairman Dr. Sean Ianchulev: The Making Of An iDoctor - Immigrant, Innovator, Inventor
21 sept. 2022 10h01 HE
|
Eyenovia
NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Before founding Eyenovia, Dr. Sean Ianchulev had established himself as a pioneer and innovator in the field of ophthalmology. Inspired by his mother, a...
Eyenovia's Novel Optejet® Dispenser Puts People's Eyes First
30 août 2022 09h01 HE
|
Eyenovia
NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, brings...
Tarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial Evaluating TP-03 for the Treatment of Demodex Blepharitis
21 juin 2021 06h00 HE
|
Tarsus Pharmaceuticals, Inc
Saturn-1 Phase 2b/3 trial met all primary and secondary endpoints, and demonstrated significant, clinically meaningful outcomes with no serious treatment-related adverse events and no...
Notal Vision secures $25 million in recent funding round for ForeseeHome® and pipeline technologies
11 déc. 2019 08h00 HE
|
Notal Vision
Manassas, VA, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Notal Vision, Inc., a privately held ophthalmic diagnostic services company focused on advancing eye care with precision medicine by extending disease...
EyeGate Announces Positive Top-line Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Post-Operative Inflammation and Pain in Cataract Surgery Patients
01 août 2016 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
The Cooper Companies Reports First Quarter 2004 Results and Updates Guidance
02 mars 2004 16h00 HE
|
The Cooper Companies, Inc.
Fiscal 2004 Guidance Raised: Revenue $480 Million to
$490 Million; EPS $2.51 to $2.54
Second Quarter 2004 Guidance: Revenue $114 Million to
...